# US 2025/0084145 A1 · Method for establishing pluripotent stem cells bearing genes encoding antigen specific t cell receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084145 A1
- Document ID: US20250084145A1
- Status: Published application
- Kind: A1
- Application number: 18/909,551
- Filed: 2024-10-08
- Published: 2025-03-13
- Earliest claimed: 2014-07-18
- Inventors: Hiroshi Kawamoto; Kyoko Masuda; Takuya Maeda; Yoshimoto Katsura
- Web page: https://patentgrep.com/patent/US20250084145A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 40/10: characterised by the cell type used
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 15/09: Recombinant DNA-technology
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2039/572: {cytotoxic response}
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a method for inducing T cells for a cell-based immunotherapy, comprising the steps of: (1) providing human pluripotent stem cells bearing genes encoding a T cell receptor specific for a desired antigen, and (2) inducing T cells from the pluripotent stem cells of step (1). The human pluripotent stem cells bearing genes encoding the desired antigen specific T cell receptor may be prepared by introducing genes encoding the desired antigen specific T cell receptor into pluripotent stem cells.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

An in vitro method for inducing T cells expressing a single T cell receptor for a cell-based immunotherapy, comprising the steps of:
(1) providing human pluripotent stem cells;
(2) introducing re-arranged genes encoding an antigen specific T cell receptor into the pluripotent stem cells; and
(3) inducing T cells from the pluripotent stem cells obtained in step (2), thereby obtaining T cells expressing said antigen specific T cell receptor as the single T cell receptor, wherein none of the genes encoding Rag 1 and Rag 2 in the pluripotent stem cells is knocked out.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the pluripotent stem cells were established from a donor with a homozygous HLA haplotype that matches at least one of HLA haplotypes of a subject to be treated.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the immunotherapy is for the treatment of a disease involving immunity.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the immunotherapy is for the treatment of a cancer.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the cancer is a WT1 gene expressing cancer.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the disease involving immunity is selected from the group consisting of a cancer, an infectious disease, an autoimmune disease and an allergic disease.

### Claim 18 (depends on 12)

The method according to claim 12, wherein the pluripotent stem cells in step (1) are established from cells of a healthy donor.

### Claim 19 (depends on 12)

The method according to claim 12, wherein the pluripotent stem cells are embryonic stem cells.
